News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News New breakthrough designations for Roche's Alecensa and Actem... Alecensa and Roactemra are breakthroughs, says FDA.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News AZ's Tagrisso first to be funded through new Cancer Drugs Fu... New-look CDF pays for lung drug Tagrisso
News Owlstone's breath-based lung cancer diagnostic could save 10... Trial's next phase will recruit 3,000 patients across 21 international sites.
News BeyondSpring looks to tap China for lung cancer drug develop... Company's alliance in huge lung cancer market could pay off
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
